WORLDSymposium 2027 awards three rare-disease pioneers, from gene therapy to patient advocacy

written by Samuel Reed · 4 days ago
Green leaf with a drop of water

The 23rd Annual WORLDSymposium™ will be held January 31–February 4, 2027, in San Diego, California, USA.

It is not every day that a scientific conference becomes a stage for stories of fierce parental resolve, groundbreaking clinical trials, and global community-building. WORLDSymposium 2027, the premier gathering focused on lysosomal diseases, is set to do exactly that by recognizing three individuals whose work has reshaped the landscape of rare disease research and patient care. The awards will be presented during the 23rd annual WORLDSymposium, running from January 31 through February 4, 2027, at the Manchester Grand Hyatt San Diego. Registration is now open for this premier international scientific meeting.

Catalyst Award
The 2027 Catalyst Award honors Karen Pignet, a biotech entrepreneur dedicated to advancing gene therapies for rare diseases. Following her daughter’s diagnosis with Sanfilippo syndrome, Ms. Pignet founded Lysogene and led an investigational gene therapy for Sanfilippo syndrome type A into an international Phase III clinical trial. She then founded Blue Daisy, a nonprofit organization that took over the program to bring the trial to completion. Her journey reflects a mother’s determination and an entrepreneur’s ability to mobilize people and resources to catalyze progress for patients and their families.

Also worth a look: OneVest double-wins at Calgary fintech symposium as 500+ crowd signals western Canada’s rising clout and Capital Markets Dad brings its family-first finance community to Calgary for new investor events.

Roscoe O. Brady Award
WORLDSymposium is pleased to announce Cynthia J. Tifft, MD, PhD, as the recipient of the 2027 Roscoe O. Brady Award. A Senior Clinician and Deputy Clinical Director at the National Human Genome Research Institute, Dr. Tifft directs the Pediatric Undiagnosed Diseases Program, where she has coordinated the evaluation of nearly 600 children whose diagnoses long eluded the medical community. Her natural history research in glycosphingolipid and glycoprotein disorders, and the first-in-human gene therapy trial she and her team launched in 2019 for Type I and Type II GM1 gangliosidosis, have expanded both the understanding of these conditions and the possibilities for treating them.

Patient Advocate Leader (PAL) Award
Daniel Lewi, Co-founder and CEO of the Cure & Action for Tay-Sachs (CATS) Foundation, will receive the 2027 Patient Advocate Leader (PAL) Award. A rare-disease parent, Mr. Lewi established the UK charity in 2011 and has grown it into an internationally recognized patient organization. Through patient registries, support for clinical research, and collaboration across the European and global GM2 gangliosidoses community, he has worked to embed the patient voice throughout therapeutic development for Tay-Sachs and Sandhoff disease.

Looking Ahead: Late-Breaking Science
In addition to these award recognitions, WORLDSymposium 2027 will feature a Late-Breaking Science session highlighting the most current discoveries and clinical advances in lysosomal research. The Call for Late-Breaking Abstracts is open through December 1, 2026, and offers investigators an opportunity to share emerging data with an international audience of scientists, clinicians, and patient advocates.

Attend in San Diego
Award honorees will be formally recognized during WORLDSymposium 2027, taking place January 31–February 4, 2027, in San Diego, California. The Catalyst Award will be presented at the Be The Catalyst event on January 31, the Roscoe O. Brady Award on February 1, and the PAL Award on February 2. The meeting happens only once a year and will convene global experts for five days of scientific sessions, poster presentations, and collaborative discussions to drive progress in lysosomal disease research and care.

Early registration rates end December 18, 2026, and the hotel room block is almost sold out. Attendees are encouraged to register and book now. Learn more and register at worldsymposia.org.

About WORLDSymposium
WORLDSymposium™ (We’re Organizing Research on Lysosomal Diseases) is an annual global medical education conference focused on lysosomal and related diseases. Now in its 23rd year, the meeting brings together more than 2,000 researchers, clinicians, patient advocates, and industry professionals from over 50 countries to exchange knowledge and advance the field. The 2027 Annual Scientific Meeting will take place January 31–February 4, 2027, at the Manchester Grand Hyatt in San Diego, California.

Why it matters: These awards highlight a critical shift in rare-disease research: progress is no longer driven solely by academic labs or pharmaceutical giants, but by parents-turned-entrepreneurs, government clinicians tackling undiagnosed cases, and advocates building cross-border communities. Their combined work offers a blueprint for how to accelerate treatments for some of the most devastating genetic conditions affecting children worldwide.

Jena Dunham
WORLDSymposium c/o Etherio Group
Visit us on social media:
LinkedIn
Facebook
YouTube
X


Samuel Reed

Samuel Reed

Samuel Reed is a senior journalist covering the intersection of business, technology, and society. With over a decade of experience, his work focuses on artificial intelligence, corporate governance, and emerging tech trends.

You May Also Like